Genotype and Phenotype in Multiple Sclerosis-Potential for Disease Course Prediction?
Vilija G Jokubaitis, Yuan Zhou, Helmut Butzkueven, Bruce V Taylor
Current Treatment Options in Neurology | CURRENT MEDICINE GROUP | Published : 2018
Helmut Butzkueven is on the Australian advisory board and Global Advisory boards for Novartis, Biogen, Merck, and Teva, and is a consultant for Novartis (Progressive MS consultancy) and Oxford Pharmagenesis (MS Brain Health Steering Committee). Dr. Butzkueven reports research grants from Biogen and Novartis and lecture fees paid to him from Biogen. Dr. Butzkueven has received payment for the development of educational presentations for Biogen (MS Atlas Meetings), Novartis (National MS workshop), and Merck (Global Registries workshop).